• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 4- Nonadherence Caused by a Lack of Access

Article

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed.

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed. “It’s certainly happening for ipilimumab,” said Dr Ribas. “In places like the county hospital it’s hard to find any patient who has been on ipilimumab because it’s not being approved for administration even though it’s an FDA-approved drug and even though there are 2 randomized trials that demonstrated improvement in survival.”

Related Videos
Joshua K. Sabari, MD
Nicoletta Colombo, MD, PhD
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
James Simon, MD – Image credit: AJMC
Brooke Aggarwal, EdD – screenshot by AJMC
Hearn Jay Cho, MD, PhD
Susan Cantrell, CEO of AMCP
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.